glp 1 dual agonist and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Mechanisms of action and effects
Description
Mol Immunol
However, evidence regarding hemodynamic effects is limited and inconsistent
Berndt SI, Gustafsson S, Mgi R, Ganna A, Wheeler E, Feitosa MF, et al
Sequence comparison among endogenous hormones, approved drugs and triple agonists revealed that the peptide sequence is conserved in the N-terminal region (residues 49), with variations primarily occurring in the middle region (residues 1021) (Fig
doi:10.1002/oby.20340 56
